Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be used to inform therapy cessation decision making. Here, Arnon Kater, PhD, of Universiteit Van Amsterdam, Amsterdam, Netherlands, gives an overview of the HOVON-141 trial (NCT03226301) that utilizes MRD negativity as an endpoint in patients with chronic lymphocytic leukemia (CLL) that are treated with a combination of venetoclax and ibrutinib. Prof. Kater also discusses the research looking at venetoclax and obinutuzumab as a pre-treatment to lower the risk of tumor lysis syndrome in patients with CLL. Prof. Kater was speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
MRD negativity as a treatment endpoint in CLL
